TY - JOUR
T1 - Alginate biomaterial for the treatment of myocardial infarction
T2 - Progress, translational strategies, and clinical outlook. From ocean algae to patient bedside.
AU - Ruvinov, Emil
AU - Cohen, Smadar
N1 - Funding Information:
The research was supported in part by grants from the Israel Science Foundation ( 793/04 and 1368/08 ), European Union Framework Programme 7 (INELPY) , and sponsored in part by BioLineRx, Jerusalem, Israel. Prof. Cohen holds the Claire and Harold Oshry Professor Chair in Biotechnology.
Publisher Copyright:
© 2015 Elsevier B.V.
PY - 2016/1/15
Y1 - 2016/1/15
N2 - Alginate biomaterial is widely utilized for tissue engineering and regeneration due to its biocompatibility, non-thrombogenic nature, mild and physical gelation process, and the resemblance of its hydrogel matrix texture and stiffness to that of the extracellular matrix. In this review, we describe the versatile biomedical applications of alginate, from its use as a supporting cardiac implant in patients after acute myocardial infarction (MI) to its employment as a vehicle for stem cell delivery and for the controlled delivery and presentation of multiple combinations of bioactive molecules and regenerative factors into the heart. Preclinical and first-in-man clinical trials are described in details, showing the therapeutic potential of injectable acellular alginate implants to inhibit the damaging processes after MI, leading to myocardial repair and tissue reconstruction.
AB - Alginate biomaterial is widely utilized for tissue engineering and regeneration due to its biocompatibility, non-thrombogenic nature, mild and physical gelation process, and the resemblance of its hydrogel matrix texture and stiffness to that of the extracellular matrix. In this review, we describe the versatile biomedical applications of alginate, from its use as a supporting cardiac implant in patients after acute myocardial infarction (MI) to its employment as a vehicle for stem cell delivery and for the controlled delivery and presentation of multiple combinations of bioactive molecules and regenerative factors into the heart. Preclinical and first-in-man clinical trials are described in details, showing the therapeutic potential of injectable acellular alginate implants to inhibit the damaging processes after MI, leading to myocardial repair and tissue reconstruction.
KW - Affinity binding
KW - Alginate
KW - Biomaterials
KW - Clinical trials
KW - Myocardial infarction
KW - Regeneration
KW - Scaffolds
KW - Tissue engineering
UR - http://www.scopus.com/inward/record.url?scp=84951775551&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2015.04.021
DO - 10.1016/j.addr.2015.04.021
M3 - Review article
AN - SCOPUS:84951775551
SN - 0169-409X
VL - 96
SP - 54
EP - 76
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
ER -